EN DE
Watch Evommune, Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Evommune, Inc. (EVMN) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Evommune, Inc. stock $3.14, price $6.65, that is 52.8% below the price, quality 46 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

EI Evommune, Inc. logo Thin data Nov 8, 2026

Evommune, Inc.

EVMN · US
Weakest Setup

Our calculation puts a fair price 53% below what the stock costs today.

Quality 46/100
Expensive Growth (revenue YoY +85.7 %/yr in USD)
Mixed vs. peers (3/7)
Insiders bought $146,260 (6M) · sold $2.3M
Fair value $3.14 · Strongly overvalued (−52.8%)
Negative free cash flow
Narrow moat 8/100 · thin data
Thin data
⚠ Dilution
Watch Evommune, Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$31.57 $5.10 Fair Value $3.14 Nov 2025 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

12‑month range $5.10 – $31.57 · fair‑value band $2.07 – $3.93 · the $6.65 price screens above the $3.14 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.

Follow Evommune in your weekly email

Every Wednesday you see whether Evommune is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States.

Show moreShow less

The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis.

Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.

Stock analysis

Evommune, Inc. (EVMN) currently trades at $6.65, while our model-based Fair Value estimate is $3.14, 53% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 88/100, which puts the data coverage at low.

Scenario range: $2.07 (bear) to $3.93 (bull), the price of $6.65 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Evommune, Inc. reported revenue of $13.0M in FY2025 versus $5.0M in FY2023, a compound +61.2%/yr. Reported net income was −$68.9M in FY2025.

Key figures

Market cap $240M Micro · P/S ratio 24.1 · EPS (TTM) $−3.75 · Return on equity −52.1% · Return on assets (EBIT) −58.0% (3-year average) · Operating margin −1,019% · Revenue (TTM) $10.0M · Free cash flow −$76.7M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 79% below its 52-week high and 30% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −53%, EVMN screens richer than that median.

Fair Value models

Bear $2.07 Fair Value $3.14 Bull $3.93
Price $6.65 · Downside -52.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) $2.44 $3.69 $4.62 52
All 1 models by family
Asset-Based
NCAV (Graham) $2.44 $3.69 $4.62 52

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 46/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 2
How much profit the company makes from its sales and capital
Quality Growth 87
Are margins and returns getting better?
Cashflow 14
Do the profits arrive as real cash?
Financial strength 91
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 3
Distance to the 52-week high, does not count
New shares 8
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 2 officers or directors bought shares worth $146,260, most recently on Jul 8, 2026. Over the same period, 6 people sold shares worth $2.3M. Buying cluster

  • BuyKyle CarverChief Financial Officer1,000 shares at $13.26$13,260Jul 8, 2026
  • BuyArthur S KirschDirector10,000 shares at $13.30$133,000Jul 7, 2026
  • SaleLuis C. PenaPresident & CEO, Director2× since Jun 1, 2026: 24,225 shares, avg. $22.73$550,653Jun 22, 202610b5-1 plan
  • SaleJanice Suzann DrewChief of Dev. Operations20,000 shares at $22.63$452,600Jun 22, 202610b5-1 plan
  • SaleJeegar Pravinkumar PatelChief Scientific Officer2× since Jun 1, 2026: 18,175 shares, avg. $22.72$412,942Jun 22, 202610b5-1 plan
  • SaleDavid E CohenDirector6,056 shares at $20.33$123,094Jun 2, 202610b5-1 plan
  • SaleGregory S. MossChief Business & Legal Officer14,223 shares at $22.83$324,711May 28, 202610b5-1 plan
  • SaleKyle CarverChief Financial Officer18,175 shares at $22.84$415,117May 28, 202610b5-1 plan
  • BuyRobert Lorne HopfnerDirector, 10% owner1,000 shares at $17.35$17,350Dec 19, 2025

Plus 6 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: only 3 usable fiscal years, at least 4 required
not computed

EVMN screens overvalued: fair value 53% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Evommune, Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 46 · Above median
Fair Value upside −52.8% · Below median
Profitability
Return on assets −30.6% · Below median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.17× · Cheaper than median
P/S (12 months) 24.03× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs EVMN
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs EVMN
Genmab A/S GMAB kr 3,527 kr 3,999 +13% vs EVMN
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs EVMN
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs EVMN
Vertex Pharmaceuticals Incorporated VRTX $547.09 $596.75 +9% vs EVMN
argenx SE ARGX $927.21 $908.40 −2% vs EVMN
CSL Limited CSL A$202.04 A$183.04 −9% vs EVMN
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs EVMN
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs EVMN

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Evommune, Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Evommune, Inc. Fair Value". https://www.fairvalue-calculator.com/stock/EVMN

Frequently asked questions

Is Evommune, Inc. (EVMN) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of $3.14 versus a price of $6.65, about 53% lower (overvalued).
What is the fair value of EVMN?
Our model-based fair value for Evommune, Inc. is $3.14 (as of Nov 8, 2026), built from audited fundamentals. The current price: $6.65.
What is the quality score of EVMN?
Evommune, Inc. has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Evommune, Inc. (EVMN)?
Our model-based price target is the fair value of $3.14 (as of Nov 8, 2026) from 1 valuation models. Cautious scenario $2.07, optimistic scenario $3.93. It is a calculation from audited fundamentals, not an analyst target.
What is the Evommune, Inc. stock forecast for 2026?
Our models put fair value at $3.14, about 53% lower versus a price of $6.65 (overvalued). Cautious scenario $2.07, optimistic scenario $3.93. The calculation is refreshed regularly with new filings.
What is the revenue of Evommune, Inc. (EVMN)?
Evommune, Inc. reported trailing-twelve-month revenue of about $10.0M (latest available figure, as of Nov 8, 2026).
What is the intrinsic value of Evommune, Inc. (EVMN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Evommune, Inc. it is $3.14 per share (as of Nov 8, 2026), against a price of $6.65. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Evommune, Inc. stock overvalued or undervalued in 2026?
As of Nov 8, 2026, EVMN trades above its calculated fair value: price $6.65, fair value $3.14, a gap of about −53% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EVMN?
No. The price is what the market pays today ($6.65); the fair value is what the company's own numbers justify ($3.14). For Evommune, Inc. the two are $3.51 per share apart. That gap is exactly why we show both numbers side by side.
How much is Evommune, Inc. worth?
The market values Evommune, Inc. at about $240M (market capitalisation, as of Nov 8, 2026). Per share that is $6.65; our models calculate a fair value of $3.14 per share.
What do the bullish and bearish scenarios say about EVMN?
Our models span a range for Evommune, Inc.: cautious scenario $2.07, base $3.14, optimistic $3.93 per share (as of Nov 8, 2026, price $6.65). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Evommune, Inc. (EVMN)?
Balance-sheet figures for Evommune, Inc. (as of Nov 8, 2026): return on equity −52.1%. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is EVMN from its 52-week high?
Evommune, Inc. trades at $6.65, about 79% below its 52-week high of $31.57 and 30% above the low of $5.10 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $3.14 is for.
Which stocks are comparable to Evommune, Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Evommune, Inc. stock attractive at the current price?
The data as of Nov 8, 2026: price $6.65, calculated fair value $3.14 (−53%), Quality Score 46/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of EVMN calculated?
We run Evommune, Inc. through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $3.14 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Evommune, Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Evommune, Inc. (EVMN)?
The closing price on Nov 6, 2026 was $6.65. Our model-based fair value is $3.14, about 53% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Evommune, Inc. right now?
The price sits above even our optimistic bull case ($3.93). The favourable scenario is already priced in. Weak quality (46/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($2.07 to $3.93) leaves room in how you read the outcome.

Key figures of Evommune, Inc.

How large is the market capitalisation of Evommune, Inc. (EVMN)?
The market capitalisation of Evommune, Inc. is $240M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Evommune, Inc. (EVMN)?
The price-to-sales ratio of Evommune, Inc. is 24.1 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Evommune, Inc. (EVMN)?
Earnings per share at Evommune, Inc. are $−3.75. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Evommune, Inc. (EVMN)?
The return on equity (ROE) of Evommune, Inc. is −52.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Evommune, Inc. (EVMN)?
On an EBIT basis the return on assets of Evommune, Inc. is −58.0% (avg 3y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Evommune, Inc. (EVMN)?
The operating margin of Evommune, Inc. is −1,019% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Evommune, Inc. (EVMN) generate?
The free cash flow of Evommune, Inc. is −$76.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Evommune, Inc. (EVMN) hold?
Evommune, Inc. holds more cash than debt, $42.0M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Evommune, Inc. in the live analysis

One click puts Evommune, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.